Shares of Cryolife Inc (NYSE:CRY) have been given an average recommendation of “Hold” by the seven research firms that are covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $23.63.

CRY has been the topic of several recent analyst reports. Canaccord Genuity restated a “buy” rating and issued a $25.00 price objective on shares of Cryolife in a report on Monday, October 9th. Lake Street Capital upped their price objective on shares of Cryolife to $26.00 and gave the stock a “buy” rating in a report on Wednesday, October 11th. Zacks Investment Research lowered shares of Cryolife from a “hold” rating to a “sell” rating in a report on Tuesday, October 17th. TheStreet lowered shares of Cryolife from a “b” rating to a “c+” rating in a report on Monday, October 30th. Finally, Northland Securities restated a “buy” rating and issued a $23.50 price objective on shares of Cryolife in a report on Monday, November 13th.

In related news, CAO Amy Horton sold 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 8th. The shares were sold at an average price of $19.00, for a total transaction of $76,000.00. Following the sale, the chief accounting officer now directly owns 98,705 shares of the company’s stock, valued at approximately $1,875,395. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director James Benson sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $22.80, for a total transaction of $45,600.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 61,190 shares of company stock worth $1,183,840. 6.00% of the stock is owned by insiders.

Large investors have recently made changes to their positions in the business. Royce & Associates LP increased its position in shares of Cryolife by 10.0% in the 2nd quarter. Royce & Associates LP now owns 435,200 shares of the medical equipment provider’s stock valued at $8,682,000 after purchasing an additional 39,500 shares during the last quarter. William Blair Investment Management LLC purchased a new stake in shares of Cryolife in the 2nd quarter valued at approximately $4,517,000. Marshall Wace North America L.P. increased its position in shares of Cryolife by 118.4% in the 2nd quarter. Marshall Wace North America L.P. now owns 133,021 shares of the medical equipment provider’s stock valued at $2,660,000 after purchasing an additional 72,114 shares during the last quarter. Prudential Financial Inc. increased its position in shares of Cryolife by 51.6% in the 3rd quarter. Prudential Financial Inc. now owns 133,863 shares of the medical equipment provider’s stock valued at $3,039,000 after purchasing an additional 45,580 shares during the last quarter. Finally, Hartford Investment Management Co. purchased a new stake in shares of Cryolife in the 3rd quarter valued at approximately $276,000. 73.28% of the stock is currently owned by institutional investors.

Cryolife (CRY) opened at $19.40 on Monday. The company has a quick ratio of 4.90, a current ratio of 5.96 and a debt-to-equity ratio of 0.29. Cryolife has a fifty-two week low of $14.02 and a fifty-two week high of $24.00. The company has a market cap of $706.59, a P/E ratio of 69.29 and a beta of 0.82.

Cryolife (NYSE:CRY) last issued its quarterly earnings data on Monday, October 30th. The medical equipment provider reported $0.08 EPS for the quarter, hitting the consensus estimate of $0.08. Cryolife had a net margin of 5.28% and a return on equity of 6.43%. The firm had revenue of $44.00 million for the quarter, compared to analyst estimates of $44.60 million. During the same period in the prior year, the business posted $0.13 EPS. The business’s revenue for the quarter was down 2.9% compared to the same quarter last year. research analysts anticipate that Cryolife will post 0.28 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/12/25/cryolife-inc-cry-receives-average-rating-of-hold-from-analysts.html.

Cryolife Company Profile

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.